Author

Cristian Fernández

Observed names: C. Fernandez, C. Fernández, C. Fernández Martínez, C. Fernández-Martínez, Cristian Fernandez, Cristian Fernandez Martinez, Cristian Fernandez-Martinez, Cristian Fernández Martínez, Cristian Fernández-Martinez, Cristian Fernández-Martínez

Institution: PharmaMar (Spain)

Observed institutions: Universitat de Miguel Hernández d'Elx, Institució Catalana de Recerca i Estudis Avançats, Brigham and Women's Hospital, Translational Genomics Research Institute, Harvard University, Tower Cancer Research Foundation, Centro de Investigación Biomédica en Red, Hospital General Universitario de Elche, PharmaMar (Spain), Dana-Farber Cancer Institute, Mayo Clinic in Arizona, Vall d'Hebron Hospital Universitari, Dana-Farber Brigham Cancer Center, Vall d'Hebron Institute of Oncology, University of Arizona Cancer Center

ORCID: 0000-0003-0333-4690

Observed ORCID: 0000-0003-0333-4690

OpenAlex ID: A5100747486

Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers

2010 · Daniel D. Von Hoff, Joseph J. Stephenson, et al. · Journal of Clinical Oncology · 647

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

2020 · José Trigo, Vivek Subbiah, et al. · The Lancet Oncology · 486

Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL)

2021 · Stephanie Gaillard, Ana Oaknin, et al. · Gynecologic Oncology · 64

Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy

2018 · Cristina Cruz, Alba Llop-Guevara, et al. · Journal of Clinical Oncology · 47

PDF

Endothelin-1 levels and biomarkers of oxidative stress in glaucoma patients

2014 · N. López-Riquelme, C. Villalba, et al. · International Ophthalmology · 45

Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment

2020 · Vivek Subbiah, Luis Paz-Ares, et al. · Lung Cancer · 41

Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study

2022 · Vivek Subbiah, Irene Braña, et al. · Clinical Cancer Research · 35

PDF

Experience Using a 3d Head-mounted Display System in Ophthalmic Surgery

2017 · José J. Martínez-Toldos, Cristian Fernández-Martínez, et al. · Retina · 32

Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors

2011 · Geoffrey I. Shapiro, Raoul Tibes, et al. · Clinical Cancer Research · 31

Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study

2022 · Federico Longo-Muñoz, Daniel Castellano, et al. · European Journal of Cancer · 19

PDF

Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours

2023 · Alexandra Leary, Ana Oaknin, et al. · European Journal of Cancer · 14

PDF

Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study

2022 · V. Boni, B. Pistilli, et al. · ESMO Open · 11

Preliminary Evaluation of the Clinical Benefit of a Novel Visual Rehabilitation Program in Patients Implanted with Trifocal Diffractive Intraocular Lenses: A Blinded Randomized Placebo-Controlled Clinical Trial

2021 · David P. Piñero, Ainhoa Molina-Martin, et al. · Brain Sciences · 11

PDF

Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study

2023 · Rebecca Kristeleit, Alexandra Leary, et al. · Investigational New Drugs · 8

PDF

SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma

2025 · Gregory M. Cote, Sant P. Chawla, et al. · Future Oncology · 6

PDF

Abstract P3-13-01: Lurbinectedin (PM01183) activity in BRCA1/2-associated or unselected metastatic breast cancer. Interim results of an ongoing phase II trial

2015 · Judit Balmaña, Cristina Cruz, et al. · Cancer Research · 5

The influence of the Artisan–Verisyse position on the postoperative outcomes: A systematic review and meta-analysis

2022 · Daniel Romero, Jaime Escolano, et al. · Indian Journal of Ophthalmology · 3

Presumed Bilateral Acute Retinal Necrosis 11 Years Apart, Atypical Presentation, and Early Vitrectomy

2015 · Aida Navarro-Navarro, Jose J. Martinez-Toldos, et al. · European Journal of Ophthalmology · 3

Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma (MPM).

2012 · Lee M. Krug, Antoinette J. Wozniak, et al. · Journal of Clinical Oncology · 3

Optical neuropathy due to inhaled cocaine, causality or chance

2020 · J. Escolano-Serrano, C.E. Monera-Lucas, et al. · Archivos de la Sociedad Española de Oftalmología (English Edition) · 2

Laser and ranibuzumab combination for retinal vasoproliferative tumor's management

2015 · C. Fernández-Martínez, J.J. Martínez-Toldos, et al. · Archivos de la Sociedad Española de Oftalmología (English Edition) · 2

Combinación de láser y ranibizumab en el manejo del tumor retiniano vasoproliferativo

2015 · C. Fernández-Martínez, J.J. Martínez-Toldos, et al. · Archivos de la Sociedad Española de Oftalmología · 2

Abstract C131: CBP501 (CBP), a novel cell cycle dysregulator, in combination with cisplatin (CDDP) and pemetrexed (PM) - pharmacokinetics (PK) in two phase I/II studies

2009 · Sunil Sharma, Raoul Tibes, et al. · Molecular Cancer Therapeutics · 2

Abstract B47: CBP501, a novel cell cycle dysregulator, in combination with cisplatin (CDDP) and pemetrexed (PM) - results of two phase I/II studies

2009 · Sunil Sharma, Raoul Tibes, et al. · Molecular Cancer Therapeutics · 2

FLACS (Femtosecond-Laser-Assisted Cataract Surgery) combined with pupiloplasty in iris-lens coloboma

2024 · German Castilla-Martinez, Cristian Fernandez-Martinez, et al. · American Journal of Ophthalmology Case Reports · 1

Works count: 49

Citation count: 1,527

H-index: 11

I10-index: 13